北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学药学院  > 药剂学系  > 期刊论文
学科主题: 药学
题名:
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
作者: Zhou, Shu-Feng1; Di, Yuan Ming; Chan, Eli2; Du, Yao-Min3; Chow, Vivian Deh-Wei; Xue, Charlie Changli; Lai, Xinsheng4; Wang, Jian-Cheng5; Li, Chun Guang; Tian, Min5; Duan, Wei6
关键词: Pharmacogenetics ; drug metabolizing enzymes ; cytochrome P450 ; CYP3C9 ; CYP2D6 ; P-glycoprotein ; single nucleotide polymorphism ; thiopurine S-methyltransferase ; beta-adrenergic receptor
刊名: CURRENT DRUG METABOLISM
发表日期: 2008-10-01
卷: 9, 期:8, 页:738-784
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
研究领域[WOS]: Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
关键词[WOS]: THIOPURINE S-METHYLTRANSFERASE ; POOR METABOLIZER PHENOTYPE ; ARYLAMINE N-ACETYLTRANSFERASE ; SINGLE-NUCLEOTIDE POLYMORPHISMS ; SEROTONIN TRANSPORTER GENE ; HUMAN LIVER-MICROSOMES ; UDP-GLUCURONOSYLTRANSFERASE 1A1 ; CYTOCHROME-P450 CYP2D6 GENE ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; INFLAMMATORY-BOWEL-DISEASE
英文摘要:

The current ′fixed- dosage strategy′ approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug′s distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta(2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

语种: 英语
WOS记录号: WOS:000260015100006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56007
Appears in Collections:北京大学药学院_药剂学系_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.RMIT Univ, Sch Hlth Sci, Div Chinese Med, Bundoora, Vic, Australia
2.Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117548, Singapore
3.Guangdong Prov Peoples Hosp, Dept Internal Med, Guangzhou, Guangdong, Peoples R China
4.Guangzhou Univ Tradit Chinese Med, Coll Acupuncture & Massage, Guangzhou 510407, Guangdong, Peoples R China
5.Peking Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Beijing 100083, Peoples R China
6.Deakin Univ, Sch Med, Waurn Ponds, Vic 3216, Australia

Recommended Citation:
Zhou, Shu-Feng,Di, Yuan Ming,Chan, Eli,et al. Clinical Pharmacogenetics and Potential Application in Personalized Medicine[J]. CURRENT DRUG METABOLISM,2008,9(8):738-784.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhou, Shu-Feng]'s Articles
[Di, Yuan Ming]'s Articles
[Chan, Eli]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhou, Shu-Feng]‘s Articles
[Di, Yuan Ming]‘s Articles
[Chan, Eli]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace